Overview
Gastrointestinal ulcers, particularly those induced by nonsteroidal anti-inflammatory drugs (NSAIDs), involve damage to the stomach or duodenal mucosa, often leading to complications such as bleeding, perforation, and obstruction 12.Diagnosis
Clinical Presentation: Abdominal pain, nausea, vomiting, hematemesis, or melena 2.
Endoscopic Evaluation: Visualization of ulcer sites, particularly in the antrum or angulus of the stomach 2.
Laboratory Tests: FBC, coagulation profile, and specific tests for occult blood in stool 2.
Grading: Severity often assessed based on symptoms and endoscopic findings, with higher risk in elderly patients 2.Management
First-Line Treatments:
- COX-2 Inhibitors: Reduced risk of ulcer complications compared to traditional NSAIDs 3.
- Proton Pump Inhibitors (PPIs): Effective in preventing NSAID-induced ulcers, especially at standard or higher doses 13.
Adjunctive Treatments:
- Misoprostol: Co-prescribed to further reduce ulcer risk when NSAIDs are necessary 3.
- H2 Receptor Antagonists: Used as an alternative or adjunct, though efficacy may be lower compared to PPIs 5.Special Populations
Elderly: Higher incidence of complications like hematemesis or melena; careful monitoring and dose adjustment recommended 2.
Comorbidities: Patients with a history of peptic ulcer disease may require more aggressive prophylactic measures 5.Key Recommendations
Use of COX-2 Inhibitors or PPIs for High-Risk Patients: Prefer COX-2 inhibitors or prescribe PPIs to reduce NSAID-induced ulcer complications (Evidence: Strong 3).
Monitor Elderly Patients Closely: Increased vigilance for complications in patients over 65 years old (Evidence: Moderate 2).
Consider Misoprostol in Selected Cases: Co-prescribe misoprostol for additional protection in patients requiring NSAIDs where other measures are insufficient (Evidence: Moderate 3).References
1 Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. The American journal of gastroenterology 2009. link
2 Chiba T, Sato K, Kudara N, Shinozaki H, Ikeda K, Sato K et al.. Upper gastrointestinal disorders induced by non-steroidal anti-inflammatory drugs. Inflammopharmacology 2008. link
3 Hawkey CJ. NSAIDs and COX-2 inhibitors: what can we learn from large outcomes trials? The gastroenterologist's perspective. Clinical and experimental rheumatology 2001. link
4 Sheldon PS, Venis MA. Purification and characterization of cytosolic and microsomal cyclophilins from maize (Zea mays). The Biochemical journal 1996. link
5 Kowalsky SF, Hamilton RA, Figge HL. Drug usage evaluation: H2-receptor antagonist use in 30 hospitals. Hospital formulary 1991. link